Company Profile

Osiris Therapeutics, Inc. is a cellular and regenerative medicine company. The Company is focused on researching, developing and marketing products in the wound, orthopedic, and sports medicine markets. The Company operates through Biosurgery business segment, which focuses on products for wound care, orthopedics, and sports medicine to harness the ability of cells and novel constructs to promote the body's natural healing. The Company's products include Grafix, Stravix, TruSkin, Cartiform and BIO4. The Company produces and distributes Grafix for acute and chronic wounds; Stravix for tendon repair; TruSkin for wound closure; Cartiform, a viable cartilage mesh for cartilage repair, and BIO4 for bone growth. The Company's BioSmart cryopreservation process retains the native characteristics and inherent functionality of tissue. Its BioSmart process includes preservation of the three dimensional (3D) matrix, endogenous growth factors, and tissue-resident cells.

Employees

Sector

Biotechnology & Medical Research

More about the company

19-03-12	Johnson & Johnson : Smith & Nephew to buy Osiris in regenerative products push	RE
12-05-17	SANOFI : Canada OKs Osiris drug; first stem cell therapy	RE

19-04-17	Osiris Therapeutics, Inc. Announces Closing of Acquisition by Smith & Nephew plc	GL
19-03-12	OSIRIS THERAPEUTICS, INC. Rigrodsky & Long, P.A. Announces Investigation of Buyout	BU
19-03-12	Osiris Therapeutics : Smith & Nephew expands in high growth regenerative medicine market through acquisition of Osiris Therapeutics, Inc.	PR
19-03-12	Osiris Therapeutics, Inc. Enters Agreement to be Acquired by Smith & Nephew plc	GL
19-01-24	Hagens Berman: Notice to Osiris Therapeutics, Inc. Investors: Less than One Week Left to File Claims to Receive Part of $18.5 Million Settlement	BU

19-03-12	Smith & Nephew : acquiert Osiris $660 mlns (médecine régénérative)
16-05-11	Osiris Therapeutics : effectuera une présentation lors de la 26e Conférence de la European Wound Management Association
16-05-11	Osiris Therapeutics : hält Präsentationen auf dem 26. Europäischen Wundkongress

Manager	Title	Age	Since
Jeffrey Levin HRO	Human Resources Officer	-	2018-10-31
Heather Hill LAW	General Counsel	-	2006-12-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
OSIRIS THERAPEUTICS, INC.	-.--%	+0.21%	-	-	0
WUXI APPTEC CO., LTD.	+0.79%	-6.16%	+49.32%	+74.50%	66.34B
LONZA GROUP AG	-0.61%	+6.29%	+11.43%	+89.93%	52.92B
ARGENX SE	+0.33%	+4.90%	+7.53%	+73.61%	54.82B
IQVIA HOLDINGS INC.	+0.74%	+2.75%	+26.31%	+45.29%	44.09B
BEONE MEDICINES AG	+3.87%	+10.15%	+20.69%	+132.73%	43.72B
REVOLUTION MEDICINES, INC.	+7.91%	+4.30%	+263.91%	+602.72%	42.13B
CELLTRION, INC.	-0.40%	+9.85%	+17.04%	+59.17%	33.96B
WUXI BIOLOGICS (CAYMAN) INC.	-1.30%	-0.68%	+37.15%	+7.04%	26.17B
GENMAB A/S	+0.52%	+5.76%	+36.81%	+26.58%	23.37B
Average	+1.17%	+4.96%	+52.24%	+123.51%	43.06B
Weighted average by Cap.	+1.37%	+4.85%	+51.31%	+128.36%

Osiris Therapeutics, Inc. Stock

Stocks

US68827R1086

Biotechnology & Medical Research

Latest news: Osiris Therapeutics, Inc.

Press Releases: Osiris Therapeutics, Inc.

News in other languages: Osiris Therapeutics, Inc.

Managers and Directors: Osiris Therapeutics, Inc.

Bio Therapeutic Drugs

Company Profile